Catamaran (NASDAQ:CTRX) shareholders had a great day, with shares up 13% after the pharmacy benefits manager (PBM) reported stellar first quarter earnings that beat on both the top and bottom lines. Revenue spiked 53% year over year to $4.9 billion, while adjusted EPS climbed 16% to $0.50 per share. The company continues to see significant lift from the 10-year contract it signed last year with Cigna to provide prescription drug benefits for the insurer's members.
That higher volume came at the price of some margin pressure, with gross margin declining to 6%. SG&A expenses climbed 30% to $131 million due to the acquisition of Restat, another PBM, for $410 million last year.
Management also reaffirmed revenue guidance of $20 billion to $21 billion and increased adjusted EPS guidnace to $2.10 to $2.22. All in all, great news across the board for the PBM. In the video below, Motley Fool health care analysts David Williamson and Michael Douglass discuss the other major takeaways from the quarter and what investors should watch for next.
Catamaran investors are happy today -- but could this stock be even better?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Catamaran. The Motley Fool owns shares of Catamaran. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.